What are the indications for surgery and the recommended surgical approaches in gastroesophageal adenocarcinoma?

Surgery for Gastroesophageal Adenocarcinoma

Surgery remains the backbone of curative-intent treatment for locally advanced resectable gastroesophageal adenocarcinoma (cT2-T4a or cN1-3), with radical transthoracic esophagectomy and en bloc two-field lymphadenectomy being the procedure of choice in fit patients 1.

Indications for Surgery

Early-Stage Disease (T1)

• Intramucosal adenocarcinoma (T1a) can be managed with endoscopic resection if there are no high-risk features 2
• Endoscopic resection is curative when: tumor is intramucosal OR has submucosal invasion <500 μm, diameter <3 cm, negative margins, and no lymphovascular invasion or poorly differentiated components 3
• Surgical resection with lymphadenectomy is required when deep endoscopic resection margins are involved or significant risk factors for lymph node metastases exist 1

Locally Advanced Disease (T2-T4a)

• All cT2 or deeper tumors require surgical resection as part of multimodality treatment 3
• The caveat: controversy exists for cT2N0 tumors regarding preoperative treatment necessity, though surgery is still indicated 1

Oligometastatic Disease

• Surgical resection after chemotherapy is weakly recommended in carefully selected patients with oligometastases 3

Recommended Surgical Approaches

Anatomic Location-Based Strategy

For distal tumors and GEJ adenocarcinoma:

• Ivor Lewis esophagectomy (abdominal and right chest access) with gastric tube conduit and oesophagogastric anastomosis in the upper mediastinum 1
• Requires dissection of lower mediastinal and suprapancreatic lymph node stations when esophageal invasion is 2-4 cm 3

For mid and upper esophageal tumors:

• McKeown procedure (abdominal, right chest, and cervical access) with reconstruction to cervical esophagus 1

For frail patients with distal tumors:

• Transhiatal esophagectomy without transthoracic access offers lower morbidity but less extensive lymphadenectomy 1

Lymph Node Dissection Requirements

The extent of lymphadenectomy should be similar regardless of histological type (adenocarcinoma vs. squamous cell carcinoma) for cT2 or deeper tumors 3. This represents a shift from historical approaches that differentiated based on histology.

For GEJ cancers with 2-4 cm esophageal invasion, dissection should include both lower mediastinal and suprapancreatic lymph node stations 3.

Minimally Invasive vs. Open Surgery

Minimally invasive esophagectomy (including robotic techniques) is weakly recommended over open esophagectomy when transthoracic approach is indicated 3, 1. The evidence supporting this includes:

• Three RCTs demonstrating lower postoperative morbidity, quicker functional recovery, and better quality of life up to 1 year with MIO 1
• Oncological endpoints (free resection margins, lymph node yield, survival) are at least noninferior to open surgery 1
• A Swedish-Finnish population study showed better long-term overall survival with MIO compared to open esophagectomy 1

Integration with Multimodality Therapy

Preoperative treatment (chemotherapy or chemoradiotherapy) should be considered in all patients with locally advanced resectable disease 1. The 2024 guidelines specifically recommend:

• Perioperative chemotherapy OR neoadjuvant chemoradiotherapy for resectable advanced GEJ cancer, based on both Eastern and Western evidence 3
• Weekly carboplatin-paclitaxel with 41.4 Gy radiation followed by esophagectomy has shown improved survival with acceptable toxicity and no increase in surgical morbidity 1

Critical Pitfalls to Avoid

1. Do not perform inadequate lymphadenectomy: En bloc two-field lymphadenectomy is essential for adequate staging and oncologic outcomes 1

2. Do not skip preoperative staging: Accurate clinical staging determines whether endoscopic resection is appropriate versus surgical resection with lymphadenectomy 2

3. Do not treat all GEJ tumors identically: The pattern of lymph node metastasis depends on tumor location, requiring tailored surgical approaches 4

4. Do not assume endoscopic resection is adequate for submucosal invasion: Once adenocarcinoma infiltrates the submucosa, lymph node metastasis risk increases substantially, requiring surgical resection 2

The surgical approach must be determined by tumor location, depth of invasion, patient fitness, and institutional expertise with minimally invasive techniques. Surgery should always be performed in high-volume centers with multidisciplinary teams capable of delivering comprehensive perioperative care 1, 5.